In-Depth Examination of Segments, Industry Trends, and Key Players in the Synthetic Blood Substitutes and Blood Products Market

The synthetic blood substitutes and blood products industry is positioned for substantial growth in the coming years, driven by advancements in medical technology and rising healthcare demands. This market's evolution reflects significant progress in addressing critical needs such as trauma care and blood shortages, setting the stage for a promising future.

Projected Expansion and Market Size of Synthetic Blood Substitutes and Blood Products
The synthetic blood substitutes and blood products market is on track for rapid expansion, expected to reach a valuation of $15.7 billion by 2030. This represents a compound annual growth rate (CAGR) of 15.6% over the forecast period. Several factors contribute to this growth, including an increase in trauma-related incidents, a growing number of surgeries among the elderly population, breakthroughs in recombinant factor development, heightened demand for universal blood substitutes, and increased investments in emergency preparedness. Key trends shaping this sector involve the emergence of oxygen-carrying substitutes, trauma-focused emergency blood alternatives, reduced reliance on donor blood, products with extended shelf lives, and adoption within military and disaster medicine fields.

Download a free sample of the synthetic blood substitutes and blood products market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21294&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Mar_PR

Leading Companies Driving the Synthetic Blood Substitutes and Blood Products Market
The market features several influential players committed to advancing synthetic blood solutions. Prominent companies include Takeda Pharmaceutical Company Limited, Fresenius Kabi AG, Baxter International Inc., Octapharma AG, Green Cross Corporation, Alliance Pharmaceutical Corporation, Hemosol Inc., Sanguine Corporation, Sangart Inc., Biopure Corporation, Tenex Therapeutics, Velico Medical, Hemarina S.A., KaloCyte Inc., Aurum Biosciences Limited, SpheriTech Limited, Dendritech Inc., HbO2 Therapeutics LLC, HemoBioTech Inc., and Somatogen Inc.
In a notable transaction in December 2024, GVS S.p.A., an Italian plastic fabrication firm, acquired blood-related assets from Haemonetics Corporation for $67.1 million. This strategic acquisition enhances GVS's focus on plasma and hospital blood management systems while broadening its product range in blood collection and filtration. Haemonetics, headquartered in the US, specializes in blood management devices, including artificial blood substitutes and related products.

Emerging Innovations and Opportunities Within the Synthetic Blood Substitutes Market
Industry leaders are increasingly investing in innovative products such as lab-grown blood vessels, which hold immense potential to improve emergency care and trauma treatment outcomes. These bioengineered blood conduits, created from human or synthetic cells, mimic the characteristics of natural arteries and veins and are intended for applications including trauma repair, dialysis, and cardiovascular surgeries.
For example, in December 2024, the US-based biotechnology company Humacyte Global, Inc. gained FDA approval for Symvess, an off-the-shelf bioengineered blood vessel designed to aid trauma patients requiring rapid revascularization. Symvess provides a safer alternative to traditional vein harvesting or synthetic grafts and is engineered for universal use, effectively restoring blood flow and preserving limbs after severe injuries.

View the full synthetic blood substitutes and blood products market report:
https://www.thebusinessresearchcompany.com/report/synthetic-blood-substitutes-and-blood-products-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Mar_PR

Dominant Segments Within the Synthetic Blood Substitutes and Blood Products Market
This market is categorized into several core segments:
1) By Type: Perfluorocarbon Based Products (PFC), Haemoglobin Based Oxygen Carriers, Synthetic Platelets, Recombinant Factors, and Blood Expanders
2) By Application: Cardiovascular Diseases, Anaemia, Organ Transplant, Injury and Trauma, and other uses
3) By End User: Hospitals and Clinics, Blood Banks, and other users

Further detailed subsegments include:
- Perfluorocarbon Based Products divided into Emulsion-Based and Non-Emulsion-Based types
- Haemoglobin Based Oxygen Carriers split into Polymerized and Crosslinked Hemoglobin products
- Synthetic Platelets classified as Platelet Substitutes and Platelet Aggregation Inhibitors
- Recombinant Factors segmented into Factor VIII, Factor IX, and others
- Blood Expanders categorized as Colloid and Crystalloid Solutions

This structured segmentation highlights the diversity and specialization within the market, reflecting tailored solutions for a broad range of medical applications.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.